TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Sponsor: Alessandro Santin · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT03832361 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03832361 Rescue Dossier →